Triple negative breast cancer is the most aggressive type of breast cancer and most difficult to treat because it is not dependent on hormones or targeted Her2 proteins for growth that we can target with meds. These tumors will often become resistant to chemotherapy within a few treatments. A new drug called Sacituzumab govitecan-hziy… Read more »
Aromatase inhibitors (hormone therapy) are used commonly in estrogen or progesterone-depending breast cancer to help prevent recurrence. They are very effective medicines and often help us avoid chemotherapy. Unfortunately they do have some significant side effects, including hot flashes, vaginal dryness, osteoporosis and joint pains. About half of patients develop some joint pain and stiffness, and… Read more »
In hormone-positive metastatic breast cancer, combination therapy with palbociclib and hormonal therapy has proven progression-free survival benefit Palbociclib is an oral drug that inhibits cell cycle growth by blocking cells from initiating initial switch to the growth cycle of cells though CDK4 (Cyclin D-Dependent Kinase) and CDK 6 inhibition. This drug has been found to… Read more »
This summer, we finally received trial results about an important clinical question: does extended aromatase inhibitor (“hormonal”) treatment of breast cancer from 5 years to 10 years affect long-term outcomes in breast cancer survivors? Post-menopausal patients with estrogen or protesterone positive breast cancer were randomized to receive either 5 years or 10 years of aromatase… Read more »
